Posted by Michael Wonder on 02 Sep 2021
CAR-T therapy Kymriah fails to get insurance benefits
2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at the Health Insurance Review and Assessment Service (HIRA) due to its hefty price tag of 500 million won ($430,884).
According to an official at HIRA, the agency’s cancer drugs benefit appraisal committee discussed whether to grant reimbursement for Kymriah.
